Rhythm Pharmaceuticals (RYTM) EBT Margin (2021 - 2026)
Rhythm Pharmaceuticals (RYTM) reported EBT Margin of 91.65% for Q1 2026, up 5945.0% year-over-year from 1.52% in Q1 2025, and down 10.39% quarter-over-quarter from 83.03% in Q4 2025.
Rhythm Pharmaceuticals (RYTM) EBT Margin (2021 - 2026) Analysis & Trends
Rhythm Pharmaceuticals (RYTM) has 6 years of EBT Margin data on file, last reported at 91.65% in Q1 2026.
- EBT Margin for Q1 2026 came in at 91.65%, up 5945.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 92.89% (up 3028.0% YoY), and the FY2025 annual result was 103.31%, up 9669.0% from the prior year.
- EBT Margin fell to 91.65% in Q1 2026 per RYTM's latest filing, from 83.03% in the prior quarter.
- Over five years, EBT Margin peaked at 527.99% in Q4 2022 and troughed at 3506.74% in Q1 2022.
- A 5-year average of 406.1% and a median of 151.11% in 2025 frame the typical range for EBT Margin.
- On a YoY basis, EBT Margin climbed as much as 1425364 bps in 2022 and fell as far as 19138103 bps in 2022.
- A 5-year view of EBT Margin shows it stood at 527.99% in 2022, then sank by 132 bps to 170.99% in 2023, then surged by 39 bps to 103.71% in 2024, then advanced by 20 bps to 83.03% in 2025, then declined by 10 bps to 91.65% in 2026.
- Business Quant data shows RYTM's EBT Margin at 91.65% in Q1 2026, 83.03% in Q4 2025, and 102.91% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 6.40% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Rhythm Pharmaceuticals | 6.59 Bn | 6.25 Bn | 52.96 Mn | -91.65% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -91.65% |
| Dec 31, 2025 | -83.03% |
| Sep 30, 2025 | -102.91% |
| Jun 30, 2025 | -95.45% |
| Mar 31, 2025 | -151.11% |
| Dec 31, 2024 | -103.71% |
| Sep 30, 2024 | -132.28% |
| Jun 30, 2024 | -109.30% |
| Mar 31, 2024 | -543.27% |
| Dec 31, 2023 | -170.99% |
| Sep 30, 2023 | -194.61% |
| Jun 30, 2023 | -242.98% |
| Mar 31, 2023 | -454.96% |
| Dec 31, 2022 | 527.99% |
| Sep 30, 2022 | -953.80% |
| Jun 30, 2022 | -494.90% |
| Mar 31, 2022 | -3,506.74% |
| Dec 31, 2021 | -2,798.84% |
| Sep 30, 2021 | -4,290.08% |
| Jun 30, 2021 | -14,748.54% |